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esponsibility of InstAbstract Qi She Pill (QSP) is a traditional Chinese medicine (TCM) prescription that has been used in
treating cervical spondylosis radiculopathy for many years. In this study, a simple and sensitive method
using ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) on a
reverse-phase C18 column was developed for the simultaneous determination of the 19 major components
in QSP. We found that the optimum mobile phase for gradient elution was 0.1% formic acid and
methanol. The correlation coefﬁcients of all calibration curves were greater than 0.99. Recoveries
measured at three concentration levels varied from 95.43% to 102.35%. Relative standard deviations of
intra- and inter-day precisions were less than 4.45%. After successfully validating our method, we then
applied it to the quantiﬁcation of 19 components in QSP products to show that this method provides a new
standard in quality assessment of TCM prescriptions containing multiple bioactive components.
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Cervical spondylosis radiculopathy (CSR) is a chronic degenera-
tive condition of the cervical spine that affects the vertebral bodies
and intervertebral disks of the neck, as well as the components of
the spinal canal. People with CSR may experience stiffness and
pain or tingling in their necks, shoulders, or arms, leading to an
impaired ability to work and a general decrease in their quality of
life1–4. Currently, few drugs can effectively control CSR. How-
ever, Qi She Pill (QSP), a traditional Chinese medicine prescrip-
tion, have been used in the clinical management of CSR for more
than 40 years. QSP inhibit inﬂammation in CSR patients, and
published reports have shown their beneﬁcial effects on cervical
intervertebral disc degeneration (New drug clinical trial documents
number: China State Drug Administration 2003L04416)5–7.
QSP is composed of six medicinals (Radix Astragali, Rhizoma
Chuanxiong, Caulis Sinomenii, Radix Stephaniae Tetrandrae,
Artiﬁcial Moschus, and Artiﬁcial Bovis Calculus). However, little
is known about the exact components of QSP; therefore, many
potential components may be responsible for their beneﬁcial
effects. Our previous quality control study of QSP suggested that
the pills are composed of astragaloside, alkaloids and ﬂavonoids,
as well as other compounds, that have antiviral and antioxidant
actions8–15 and that have been clinically used in the therapeutic
treatment of rheumatoid arthritis (RA) because of their remarkable
anti-inﬂammatory properties.
In Chinese medicines, some active components are regarded as
indices of quality control in prescriptions. Currently, only astra-
galoside IV and sinomenine are used as indices for quality control
in the preparation of QSP16. However, it is well known that
analysis of just a single or even a few marker compounds is not
enough for good quality control of complex herbal products. Thus,
an accurate and reliable method that assesses the multiple
constituents of QSP is urgently needed to maintain safety by
accurately monitoring quality control of QSP, as well as to
enhance the efﬁcacy of QSP in CSR control.
Thus, in this study, a simple, accurate and reliable UHPLC/MS
method was developed for the simultaneous determination of the
following 19 active components of QSP: (1) gallic acid (GA), (2)
sinomenine (SIN), (3) calycosin (CCS), (4) calycosin-7-O-β-D-
glucoside (CCSG), (5) tetrahydroepiberberine (THPB), (6) (þ)-tet-
randrine (TET), (7) tetrahydropalmatine (THP), (8) fangchinoline
(FAN), (9) berberine (BER), (10) palmatine (PAL), (11) senkyu-
nolide I (SEI), (12) ononin (ONO), (13) 5-O-methylvisammioside
(5-O-M), (14) daidzein (DAI), (15) formononetin (FOR), (16)
senkyunolide A (SEA), (17) astragaloside III (AST-III), (18)
astragaloside IV (AST-IV), and (19) cholic acid (CA) (Fig. 1).
Five batches of prescription extracts were used in this study. Our
results indicate that the method proposed by us is particularly suit-
able for the routine analysis and quality control of QSP. Furthermore,
we suggest that our established method would be applicable for
quality control in the study of other compounds in TCM.2. Materials and methods
2.1. Materials and reagents
The herbal portions of QSP, including, Radix Astragali, Rhizoma
Chuanxiong, Caulis Sinomenii, Radix Stephaniae Tetrandrae,
Artiﬁcial Moschus, and Artiﬁcial Bovis Calculus were purchased
from Shanghai Kangqiao Pharmaceutical Co., Ltd. Standards ofGA (110831-201003, 498%), SIN (110774-200507, 498%),
TET (110711-200708, 498%), FAN (110793-200605, 498%),
BER-HCl (110713-200911, 498%), PAL-HCl (110732-200907,
486%), AST-IV (110781-200613, 498%), and CA (100078-
200414, 498%) were provided by the Chinese National Institute
for the Control of Pharmaceutical and Biological Products (Beij-
ing, China). Standards of CCS (120628, 498%), CCSG (121219,
497%), SEI (120728, 496%), ONO (120531, 498%), 5-O-M
(120620,498%), DAI (120829,498%), FOR (120227,498%),
SEA (120828, 496%), and AST-III (120615, 498%) were
purchased from Sichuan Weikeqi Biotech Co., Ltd. (Sichuan,
China). Standards for THPB (10421-201207, 498%), TET
(110711-200708,498%), and THP (20302-201204,498%) were
purchased from Nanchang Beta Biotech Co., Ltd. (Nan chang,
China).
HPLC-grade methanol was obtained from Dikma Technologies
Inc. (USA). Formic acid (HPLC-grade) was purchased from CNW
Technologies GmbH (Düsseldorf, Germany). Deionized water was
puriﬁed using the Milli-Q Reagent Water System (Millipore,
Bedford, MA, USA). All other reagents were of analytical grade.
2.2. Chromatographic and mass spectrometric conditions
The Dionex 3000 UHPLC system equipped with Thermo TSQ
quantum Access MAX triple quadruple mass spectrometry was
used for the chromatographic analysis. All separations were
carried out on a Waters Acquity UPLC BEH C18 column
(50 mm 2.1 mm, 1.7 μm). The mobile phase consisted of (A)
methanol and (B) aqueous formic acid (0.1%, v/v) using the
following gradient elution: 20% A at 0–1 min, 20%–100% A at 1–
8 min, 100% A at 8–12 min, 20% A at 12.1–16 min. The re-
equilibration time was 4 min. The temperature of the column oven
was 40 1C. The solvent ﬂow rate was 0.3 mL/min. Nitrogen was
used as the sheath and auxiliary gas, and Argon was used as the
damping and collision gas. Ion spray voltage was set at 3.5 kV(þ)
and 2.5 kV( ), tube lens offset at 184 V(þ) and 141 V( ),
sheath gas rate at 35 psi, and auxiliary gas ﬂow rate at 1.5 L/min.
2.3. Standard preparation
Nineteen stock solutions were prepared by dissolving 1.0 mg of
each standard in 10 mL of methanol. Appropriate volumes of each
stock solution were mixed together. Then, the mixture was diluted
serially to prepare the reference working solutions.
2.4. Sample solution preparation
Twenty QS pills of each batch (ﬁve batches, 701, 702, 703, 704,
801, are from the same Shanghai Huanghai Pharmaceutical Co.,
Ltd.) were ground into powder by using a pestle and mortar, and
0.10 g of the powder was ultrasonically extracted with 50 mL of
100% (v/v) methanol for 20 min at 30 1C, and cooled at room
temperature. The supernatant was subsequently ﬁltered through a
0.22 μm membrane. An aliquot of 2 μL of the solution was
injected into the UHPLC–MS/MS system for analysis.
2.5. Method validation
2.5.1. Linearity and sensitivity
A series of working solutions for all the standard substances were
prepared by serial dilutions with methanol. Linearity was assessed
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Figure 1 The chemical structures of the 19 selected major compounds of QSP. (1) Gallic acid (GA), (2) sinomenine (SIN), (3) calycosin (CCS),
(4) calycosin-7-O-β-D-glucoside (CCSG), (5) tetrahydroepiberberine (THPB), (6) (þ)-tetrandrine (TET), (7) tetrahydropalmatine (THP), (8)
fangchinoline (FAN), (9) berberine (BER), (10) palmatine (PAL), (11) senkyunolide I (SEI), (12) ononin (ONO), (13) 5-O-methylvisammioside
(5-O-M), (14) daidzein (DAI), (15) formononetin (FOR), (16) senkyunolide A (SEA), (17) astragaloside III (AST-III), (18) astragaloside IV (AST-
IV), and (19) cholic acid (CA).
Zhongliang Zhang et al.386by assaying calibration curves in three replicates with standard
working solutions containing a deﬁned concentration range
(GA, SIN, CCS, CCSG, THPB, TET, THP, FAN, BER-HCl,
PAL-HCl, SEI, ONO, 5-O-M, DAI, FOR, SEA, AST-III, AST-IV,
and CA).
The sensitivity of the method was evaluated by determining the
limit of detection (LOD) and the limit of quantiﬁcation (LOQ).
The LOD was determined as the sample concentration (S) resulting
in a peak height greater than three times the baseline noise level(N) (S/N¼3). The LOQ was estimated as a signal 10 times greater
than that of the baseline noise.2.5.2. Precision
Intra-day precision and accuracy were assessed by assaying
the mixed standard solution samples for three concentrations
(n¼6) on the same day. The same procedure was performed once
a day for 3 consecutive days to determine inter-day precision.
Figure 2 Typical chromatograms of UHPLC–MS/MS for (a) mixed standard substance and (b) sample.
Simultaneous determination of nineteen major components in Qi She Pill 387
Zhongliang Zhang et al.3882.5.3. Repeatability
In order to conﬁrm repeatability, six independent sample solutions
of QSPs were treated and analyzed as described above. The relative
standard deviation (RSD) was taken as a measure of repeatability.
2.5.4. Recovery
A recovery test was conducted to evaluate the accuracy of our
method. Accurate amounts of 19 standards were added to a QSPs
sample, which was then processed and analyzed as described in
the Section 2.2. The total amount of each analyte was calculated
from the corresponding calibration curve, and the recovery of each
analyte was calculated by using the following equation:
Recovery ð%Þ ¼ ðAmountdeterminedAmountoriginalÞ=Amountspiked
100%
where Amountdetermined is the total amount of each analyte determined,
Amountoriginal is the original amount of each analyte determined in
samples, and Amountspiked is the spiked amount of each analyte.
2.5.5. Stability
Stability was tested by assaying the samples; the same sample
solution was stored at 4 1C and analyzed every 12 h for 2 days. In
addition, the 19 standard stock solutions were examined by ultra-
high-performance liquid chromatography–tandem mass spectro-
metry every three days to investigate whether obvious degradation
had occurred under the preservation condition.3. Results and discussion
3.1. Optimization of extraction conditions
For efﬁcient extraction of the active components in QSP,
important factors such as methanol concentration (50%, 75%,
and 100%, v/v), ultrasonic time (20, 30 and 40 min) and sample-
solvent ratio (1:250, 1:500 and 1:750, w/v) were investigated byTable 1 Mass spectrometric parameters and fragment spectrum of a
Compound Abbreviations Ionization
mode
Monitoring
mode
Gallic acid GA ESI [MH]
Sinomenine SIN ESIþ [MþH]þ
Calycosin CCS ESIþ [MþH]þ
Calycosin-7-O-β-D-
glucoside
CCSG ESIþ [MþH]þ
Tetrahydroepiberberine THPB ESIþ [MþH]þ
(þ)-Tetrandrine TET ESIþ [MþH]þ
Tetrahydropalmatine THP ESIþ [MþH]þ
Fangchinoline FAN ESIþ [MþH]þ
Palmatine PAL ESIþ [MþH]þ
Senkyunolide I SEI ESIþ [MþH]þ
5-O-Methylvisamminol 5-O-M ESIþ [MþH]þ
Ononin ONO ESIþ [MþH]þ
Daidzein DAI ESIþ [MþH]þ
Formononetin FOR ESIþ [MþH]þ
Astragaloside IV AST-IV ESIþ [MþH]þ
Cholic acid CA ESI [MH]
Astragaloside III AST-III ESIþ [MþNa]þ
Senkyunolide A SEA ESIþ [MþH]þ
Berberine BER ESIþ [MþH]þusing an orthogonal L9 (3
4) design. The results revealed that 500
times of 100% (v/v) methanol for 20 min was the optimum sample
extraction condition.
3.2. Optimization of UHPLC–ESI/MS conditions
The 19 marker compounds were selected to obtain the optimum
elution conditions because they belong to different chemical
classes and cover a wide range of polarities. Thus, alterations in
the various UHPLC parameters, including the mobile phase
modiﬁer, ﬂow rate, and column temperature, were investigated.
Based on sensitivity, we found that the optimum UHPLC
conditions were obtained when the mobile phase modiﬁer was
0.1% formic acid. Separation was better when the column
temperature was kept at 40 1C and ﬂow rate was 0.3 mL/min
(Fig. 2).
The detection model of MS was selected in the experiment, the
organic acids (CA, GA) in the negative ion mode are excellent to
produce quasi-molecular ion [M-H]. However, the alkaloids
(SIN, PAL, BER, THPB, TET, THP, FAN), saponins (AST-IV),
lactones (SEI, SEA) and ﬂavonoids (CCS, CCSG, ONO, 5-O-M,
DAI, FOR) are optimal to produce quasi-molecular ion [MþH]þ
in positive ion mode. Nevertheless, in this mode, the adduct ion
peak [MþNa]þ is the best for AST-III.
Quantitative analysis was performed by monitoring [MþH]þ,
[MþNa]þ or [MH] for analytes in selective reaction monitor-
ing (SRM) mode. The 19 components were identiﬁed by compar-
ing their retention times, the [MþH]þ [MþNa]þ or [MH] , and
MS/MS fragments with those of reference standards. The results
showed that the highest sensitivity was obtained at a certain value
of fragment collision energy (CE) (Table 1).
3.3. Method validation
Full calibration curves of the 19 compounds were obtained with
relatively wide concentration ranges, and the correlation coefﬁcientsnalytical compounds.
Parent
(m/z)
Product
(m/z)
Tube lens
(V)
Collision energy
(eV)
RT
(min)
169.16 125.30 75 16 0.61
330.25 152.30 95 58 0.96
285.16 270.30 99 23 3.84
447.24 285.30 98 20 3.86
340.23 192.30 99 27 3.90
609.42 367.40 103 39 3.92
356.26 192.30 103 27 4.08
623.44 381.40 130 40 4.14
352.23 336.30 89 29 4.57
225.17 207.30 86 8 4.78
453.27 291.30 108 22 5.03
431.25 269.30 97 17 4.98
255.14 199.30 105 23 5.17
269.20 197.30 97 34 6.34
785.60 143.40 143 14 7.74
407.45 343.50 141 35 7.88
807.53 335.30 184 57 7.81
193.20 91.40 86 24 6.47
336.19 320.28 94 30 4.51
Table 3 Intra-and inter-day variability and stability of the 19 components.
Compound Concentration (μg/mL) Intra-day (n¼6) Inter-day (n¼6) Stability (n¼5)
Observed RSD% Observed RSD% RSD%
GA 0.201 0.19970.001 2.22 0.19770.001 1.19 2.59
1.015 1.01770.016 1.61 1.00970.009 0.89
5.075 5.06770.121 2.34 5.05070.044 0.87
SIN 0.490 0.49270.004 0.72 0.49770.021 4.23 2.52
2.450 2.44170.022 0.91 2.43270.030 1.23
11.250 11.23070.091 0.81 11.27470.218 1.92
CCS 1.009 1.00170.045 4.45 1.00370.008 0.83 2.63
5.045 5.03970.192 1.71 5.02170.031 0.61
25.225 25.19570.976 3.86 25.17870.424 1.69
CCSG 0.060 0.05870.000 0.21 0.05970.001 1.31 0.74
0.301 0.29470.009 3.06 0.29970.011 3.68
1.506 1.49170.020 1.36 1.49770.007 0.45
THPB 0.394 0.38970.018 4.12 0.39270.012 2.93 1.81
1.970 1.94370.024 1.24 1.94470.009 0.46
9.850 9.68970.010 0.10 9.68970.310 3.21
TET 0.997 0.98970.022 2.22 0.98770.005 0.53 1.96
4.985 4.89270.021 0.44 4.88270.084 1.72
24.925 24.90770.828 3.34 24.91470.712 2.86
THP 0.049 0.04970.000 2.05 0.04970.000 2.66 1.36
0.245 0.24670.006 2.43 0.24470.008 3.24
12.560 12.45470.316 2.53 12.49570.132 1.03
FAN 0.499 0.49170.002 0.41 0.43670.005 1.25 1.23
2.495 2.49970.025 1.00 2.47470.019 0.77
12.475 12.46470.411 3.29 12.48270.325 2.60
PAL 0.100 0.99770.010 1.07 0.98770.011 1.11 1.44
0.501 0.49370.004 0.81 0.48170.017 3.53
2.506 2.48670.029 1.16 2.49070.061 2.60
Table 2 Method validation for the determination of 19 selected markers.
Compound Linearity R2 Linear range (μg/mL) LOQ
(ng/mL)
LOD
(ng/mL)
Repeatability RSD (%) Recovery
Mean (%) RSD (%)
GA y¼282812xþ24.416 0.9995 0.005–0.751 5.00 1.00 2.35 98.73 0.02
SIN y¼2926.5xþ222087 0.9999 0.125–50.074 1.00 0.20 1.07 99.32 1.01
CCS y¼71.833xþ15326 0.9996 0.050–37.500 50.00 10.00 1.62 97.92 1.98
CCSG y¼28401xþ505043 0.9994 0.015–2.250 1.00 0.20 1.59 97.33 2.71
THPB y¼21441xþ28069 0.9998 0.001–0.201 1.00 0.20 2.60 100.37 1.65
TET y¼3569.2xþ20912 0.9999 0.025–3.750 2.50 0.50 1.83 100.05 1.29
THP y¼65754xþ52637 0.9998 0.001–0.188 0.40 0.08 1.37 97.79 2.32
FAN y¼140.33xþ1012.8 0.9997 0.101–20.020- 10.00 2.00 0.82 97.67 1.39
PAL y¼59845xþ168187 0.9998 0.001–0.502 1.00 0.20 1.52 95.43 3.35
SEI y¼2006.1xþ518976 0.9998 0.050–25.005 15.00 3.00 1.37 98.28 1.40
5-O-M y¼2468.9xþ7624 0.9999 0.002–1.125 1.00 0.20 2.31 99.52 0.19
ONO y¼8931.9xþ48181 0.9996 0.005–1.125 5.00 1.00 0.82 99.25 2.95
DAI y¼1910.2xþ2638.8 0.9999 0.003–0.500 2.50 0.50 1.16 100.99 0.60
FOR y¼3897.8xþ33528 0.9999 0.005–1.500 5.00 1.00 0.71 101.34 2.16
AST-IV y¼84.323xþ2717.1 0.9998 0.040–6.001 40.00 8.00 1.99 95.87 0.63
CA y¼255.55xþ12167 0.9999 0.015–22.500 15.00 3.00 2.01 101.37 0.73
AST-III y¼567.31x4102.5 0.9994 0.015–2.503 12.50 2.50 1.10 99.87 1.34
SEA y¼135.55xþ15755 0.9999 0.010–37.500 10.00 2.00 1.68 98.98 0.54
BER y¼72211xþ19097 0.9998 0.001–0.100 0.50 0.10 1.47 102.35 0.24
LOD is limit of detection; LOQ is limit of quantiﬁcation; RSD is relative standard deviation; see Table 1 for abbreviation deﬁnitions of the 19
compounds.
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Table 3 (continued )
Compound Concentration (μg/mL) Intra-day (n¼6) Inter-day (n¼6) Stability (n¼5)
Observed RSD% Observed RSD% RSD%
SEI 1.001 0.99970.013 1.30 0.99770.005 0.50 2.91
5.005 5.01370.174 3.43 5.01170.097 1.98
25.251 25.18870.405 1.61 25.22470.219 0.86
5-O-M 0.030 0.03070.000 2.19 0.03070.000 1.45 1.33
0.150 0.14970.002 1.34 0.14870.000 0.36
0.750 0.73770.003 0.48 0.72870.004 0.82
ONO 0.031 0.03070.001 3.33 0.03070.000 0.52 2.45
0.155 0.15670.001 0.64 0.15370.000 0.74
0.775 0.76370.019 2.49 0.76670.015 1.95
DAI 0.009 0.00970.000 1.71 0.00970.000 4.21 2.83
0.045 0.04670.001 2.15 0.04670.001 2.78
0.226 0.22270.003 1.35 0.22370.003 1.99
FOR 0.041 0.04170.000 1.52 0.04170.008 0.29 0.97
0.205 0.20270.005 2.47 0.20170.003 1.49
1.025 1.01770.030 2.94 1.00970.024 2.37
AST-IV 0.161 0.15870.006 3.79 0.16370.007 4.29 1.89
0.805 0.79970.010 1.25 0.78070.009 1.15
4.025 4.01170.113 2.82 4.02170.026 0.64
CA 0.299 0.27370.009 3.29 0.23270.003 0.83 2.42
1.495 1.47570.024 1.62 1.47570.029 1.96
7.475 7.50070.031 0.41 7.52970.059 0.78
AST-III 0.499 0.47470.007 1.47 0.47570.012 2.53 0.97
2.475 2.46670.022 0.89 2.44470.031 1.27
12.375 12.28070.115 0.93 12.24870.202 1.64
SEA 1.001 0.99870.020 2.01 0.99870.028 2.81 2.86
5.005 5.01170.099 1.97 5.00670.017 0.34
25.025 24.97470.804 3.21 24.93070.614 2.46
BER 0.002 0.00270.000 0.82 0.00270.000 1.01 0.20
0.010 0.01070.000 0.35 0.01070.000 1.32
0.050 0.49870.003 0.61 0.47670.005 1.05
Zhongliang Zhang et al.390of all the calibration curves were greater than 0.9990. For different
components, the LOD ranged from 0.2 ng/mL to 8 ng/mL, and the
LOQ ranged from 0.4 ng/mL to 50 ng/mL. The recoveries were
95.4%–104% and the RSD values were less than 3.35% (Table 2).
The intra-day and inter-day accuracies for the 19 compounds were
96.5–105% and 94.8–105%, respectively. The RSD values of the
intra-day and inter-days precisions were 0.21–4.45% and 0.29–
4.23%, respectively. The mixed standard solution samples were
found to be stable from 0 to 24 h and their RSD values was less
than 2.91%. RSD values for the repeatability of the analysis
ranged from 0.71% to 2.60% (Table 3).3.4. Sample analysis
QSP is selected as the object of this study is based on its excellent
clinical efﬁcacy. As it is a famous traditional Chinese prescription,
QSP has long been investigated. Reference standards are the keys
to quality control of its bioactivities. The major bioactive
components in QSP include lactones, saponins, alkaloids, ﬂavo-
noids, organic acids. The newly established analytical method wassubsequently applied to determine the 19 compounds: 2 lactones
(11, 16), 2 organic acids (1, 19), 2 saponins (17, 18), 6 ﬂavonoids
(3, 4, 12, 13, 14, 15), 7 alkaloids (2, 5, 6, 7, 8, 9, 10). The target
compounds were identiﬁed based on comparison of retention time
and mass information obtained from LC–MS analysis of the
standard compounds. Quantitative analyses were performed by
means of external standard methods.
In accordance with the Pharmacopoeia of China, astragaloside
IV (18) is a commonly used chemical marker, and it is used to
represent saponins in most cases when preparations containing
Radix Astragali are evaluated. Indeed, astragaloside IV has long
been known to show antivirus, and antioxidant17–21, pharmacolo-
gical actions in immune and circulatory systems, supplemental
calcium on bone mineral density and bone metabolism, etc.
However, the curative effects of TCMs are due to a number of
bioactive compounds, not just one22, ﬂavonoids are another
important family of bioactive chemicals due to their hepatoprotective,
antioxidative, antiviral and antihypertensive effects, their immunosti-
mulant properties, their ability to strengthen general resistance, etc.23.
Therefore, two saponins and six ﬂavonoids derived from Radix
Astragali were used as chemical markers in QSP.
Figure 3 Contents of tested compounds in the ﬁve batches of (a) organic acids; (b) lactones; (c) saponins; (d) ﬂavonoids; (e) alkaloids.
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FAN (8) exhibited the highest concentrations, followed by SIN
(2). These two components are known to have immunosuppres-
sive, anti-inﬂammatory, antinociceptive effects24–27. The volatile
oil, however, has also demonstrated lots of bioactive effects, such
as vasorelaxation28, anti-inﬂammatory29, and so on. Therefore, we
chose two major compounds from the volatile oil of Rhizoma
Chuanxiong, as chemical markers in the study. Based on their
biological functions, the compounds we selected—nineteen in all
—were reasonable and suitable as chemical markers that could be
used to evaluate the bioactivity of this formula.
Most study for TCM quality evaluation was focus on different
pharmaceutical companies on the same products rather than one
pharmaceutical company on different batches30–32. We convinced that
the determination of various ingredients in different batches made by
the same pharmaceutical company can truly reﬂect the preparation
quality. Therefore, in this study, ﬁve batches of prescription extracts
of the same pharmaceutical company were used in this study. The
results indicated that the amount of most components determined is
similar in different batches. However, the content of some compo-
nents in ﬁve batches, such as CCSG, TET, FAN, SEI, SEA, ONO,
DAI, 5-O-M, was variable (Fig. 3). This phenomenon may occur for
several reasons, the quality of herbal medicine, including seasonal
changes, harvesting time, cultivation sites, post-harvesting processing,
which may inﬂuence the content of some components determined in
QSP. In addition, the intra-batch variability of determination may also
contribute to the variation of contents.
The discrepancy of some ingredients in difference batches conﬁrm
that just a few marker compounds (astragaloside IV, sinomenine)and
one batch was not enough for good quality control of complex herbal
products. Thus, in the present study 19 determined compounds could
be considered as quality control markers for the continuous research on
QSP quality. The simultaneous determination of the major components
of QSP provides a basis for quality control and material base
investigation of the pharmacological effects of QSP.4. Conclusions
A variety of analytical methods were established for analyzing chemical
constituents of QSP16,33, but these methods only focused on the deter-
mination of a single or a few marker compounds, which, might not
accurately reﬂect the quality of the complex herbal products34.
Therefore, it was necessary to develop a relatively simple and
efﬁcient method for the quality control of QSP. Thus, we have
developed and validated a simple and rapid UHPLC–MS/MS
method for the simultaneous determination of 19 active com-
pounds in QSP. High repeatability, intra-day and inter-day
precision, accuracy, and recovery were achieved with this method
in our validation procedure. Thus, our proposed method could
improve quality control for QSP. Moreover, the results provide a
basis for further research of the prescription in vivo.
This is the latest report where the evaluation of commercial
products with as many as 19 bioactive constituents is considered.
This method of determining many bioactive compounds simulta-
neously will play an important role in the further development of
TCM compound preparations and their products.
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